한글목차

약제 요약

로페라미드는 오피오이드 계열의 약물로 장의 평활근에 직접 작용하여 장의 움직임을 감소시켜 작용하며, 흡수가 적기 때문에 전신에 영향을 미치지 않습니다. 현재 치료 지침의 권장 사항은 변실금, 배변 횟수, 변 무게의 효과적인 감소를 기반으로 합니다. 로페라미드의 용량은 처음 4mg, 이후 2-4시간마다 2mg 또는 대변이 형성되지 않은 후 1회 2mg을 복용하며, CID, 특히 일리노테칸 함유 요법의 경우 더 적극적인 요법을 선택해야 합니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 화학요법에 수반하는 설사(CID)용 로페라미드에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 CID에서의 로페라미드 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 로페라미드 시장 평가

• CID에서 로페라미드의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장 CID용 로페라미드의 시장 규모
• 시장 분석 : 국가별
  • 미국에서 CID용 로페라미드의 시장 규모
  • 독일에서 CID용 로페라미드의 시장 규모
  • 영국에서 CID용 로페라미드의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"Loperamide Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about loperamide for Chemotherapy-induced Diarrhea (CID) in the seven major markets. A detailed picture of the loperamide for CID in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the loperamide for CID. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the loperamide market forecast analysis for CID in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CID.

Drug Summary:

Loperamide is an opioid which functions by decreasing intestinal motility by directly affecting the smooth muscle of the intestine and has no systemic effects due to a minimal absorption. The recommendation in current treatment guidelines is based on an effective reduction in fecal incontinence, frequency of bowel movements and stool weight. The dosage of loperamide is an initial 4 mg dose followed by 2 mg every 2-4 hours or after every unformed stool. In case of CID, especially irinotecan-containing therapies, the more aggressive regimen should be chosen.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the loperamide description, mechanism of action, dosage and administration, research and development activities in Chemotherapy-induced Diarrhea (CID).
• Elaborated details on loperamide regulatory milestones and other development activities have been provided in this report.
• The report also highlights the loperamide research and development activities in CID across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around loperamide.
• The report contains forecasted sales of loperamide for CID till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CID.
• The report also features the SWOT analysis with analyst views for loperamide in CID.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Loperamide Analytical Perspective by DelveInsight

• In-depth Loperamide Market Assessment

This report provides a detailed market assessment of loperamide for Chemotherapy-induced Diarrhea (CID) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Loperamide Clinical Assessment

The report provides the clinical trials information of loperamide for CID covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chemotherapy-induced Diarrhea (CID) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence loperamide dominance.
• Other emerging products for CID are expected to give tough market competition to loperamide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of loperamide in CID.
• Our in-depth analysis of the forecasted sales data of loperamide from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the loperamide in CID.

Key Questions:

• What is the product type, route of administration and mechanism of action of loperamide?
• What is the clinical trial status of the study related to loperamide in Chemotherapy-induced Diarrhea (CID) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the loperamide development?
• What are the key designations that have been granted to loperamide for CID?
• What is the forecasted market scenario of loperamide for CID?
• What are the forecasted sales of loperamide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to loperamide for CID?
• Which are the late-stage emerging therapies under development for the treatment of CID?

Table of Contents

1. Report Introduction

2. Loperamide Overview in CID

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Loperamide Market Assessment

• 5.1. Market Outlook of Loperamide in CID
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Loperamide in the 7MM for CID
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Loperamide in the United States for CID
  • 5.3.2. Market Size of Loperamide in Germany for CID
  • 5.3.3. Market Size of Loperamide in France for CID
  • 5.3.4. Market Size of Loperamide in Italy for CID
  • 5.3.5. Market Size of Loperamide in Spain for CID
  • 5.3.6. Market Size of Loperamide in the United Kingdom for CID
  • 5.3.7. Market Size of Loperamide in Japan for CID

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options